chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vomiting; Diarrhea; Stomach cramping which lasted for 5 days; For 5 days following ''I'' had daily headaches; For 2 days following the 2nd dose had 101 fever/ 10 days following a fever of 102; Nausea; Muscle aches; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0151) via an unspecified route of administration in the left arm on 07Apr2021 at 15:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. Medical history included seasonal asthma and allergy to sulfa. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. Concomitant medication included estradiol/ norethisterone acetate (COMBIPATCH), for an unknown indication from an unknown date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP7534) via an unspecified route of administration in the left arm on 17Mar2021 at 15:30 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. On 09Apr2021, 2 days following the 2nd dose, the patient experienced 101 (unspecified units) fever, nausea and muscle aches. On 12Apr2021, 5 days following dose, the patient experienced headaches daily. On 17Apr2021, 10 days following, the patient experienced a fever of 102 (unspecified units), vomiting and diarrhea which lasted for 36 hours and stomach cramping which lasted for 5 days. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/ department or urgent care. On 20Apr2021, the patient underwent lab test which included SARS-CoV-2 RNA, QL, RT PCR via nasal swab and the result was negative. Therapeutic measures were not taken as a result of the reported events. Since the vaccination, the patient had been tested for COVID-19. The clinical outcome of the events fever, nausea, muscle aches, headaches were resolved on an unknown date in Apr2021 whereas vomiting and diarrhea were resolved on 18Apr2021, after the duration of 36 hours. The clinical outcome of the event stomach cramping was resolved on 22Apr2021, after the duration of 5days.  No follow-up attempts are needed. No further information is expected.
Patient received #5 Anthrax left arm on 08/16/2005.  Patient complained of swelling, shoulder/back pain, headache, radiating pain down left arm, and throbbing sensation, as of 08/17/2005.
CHILLS; FEVER; SEVERE HEADACHE; NAUSEA; FATIGUE; LIGHTHEADEDNESS; FEELING OF NOT HERSELF (DESCRIBED LIKE BEING IN A FISHBOWL); LEGS MUSCLE TIGHTNESS; LOSS OF APPETITE; BILATERAL LEG WEAKNESS; This spontaneous report received from a patient concerned a 32 year old female. The patient's height, and weight were not reported. The patient's concurrent conditions included non alcoholic, and non smoker, and other pre-existing medical conditions included patient had no known allergies and did not had any history of drug abuse/illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1808980 expiry: UNKNOWN) dose was not reported, administered on 08-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On APR-2021, the subject experienced lightheadedness. On APR-2021, the subject experienced feeling of not herself (described like being in a fishbowl). On APR-2021, the subject experienced legs muscle tightness. On APR-2021, the subject experienced loss of appetite. On APR-2021, the subject experienced bilateral leg weakness. On APR-2021, the subject experienced nausea. On APR-2021, the subject experienced fatigue. On 08-APR-2021, the subject experienced chills. On 08-APR-2021, the subject experienced fever. On 08-APR-2021, the subject experienced severe headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from lightheadedness, feeling of not herself (described like being in a fishbowl), nausea, and fatigue on 16-APR-2021, loss of appetite on APR-2021, chills, and fever on 11-APR-2021, and severe headache on 08-APR-2021, and was recovering from bilateral leg weakness, and legs muscle tightness. This report was non-serious.
Local swelling on left arm and blistering rash at site of injection (swelling to elbow) from 24-48 hrs, then resolved. Then on day #5 she developed a maculopapular rash across abdomen and thighs. No vesicles.
Arm redness, muscle ache, and itching after four days. Itching and redness subsided but still have muscle ache in bicep area of arm during movement.
Tender mass on left detoid, risk of bleeding, infection, discomfort.  Complete removal and scar formation, but after surgery it grew back in 3 months.  Itching and dryness and sting.  (KENOLOG injection) *came out right after the shot*.  2/24/09 MR received from derm dated 12/1/06-8/29/07.  Pt presented 12/1/06 for eval of firm tender keloidal mass on the L deltoid. Removed by excision with full thickness flap. Dx:  Keloid L deltoid. Seen for stitch removal and acne 12/15/06.  Keloid had recurred by 6/07. Tx steroid cream.
On 10/19/99, the pt developed generalized weakness, left arm weakness, and left deltoid pain. The pt was seen by the nurse practitioner and prescribed ibuprofen and referred to an occupational therapist.
LEFT ARM WEAKNESS. UNABLE TO BEAR MUCH WEIGHT AT ALL.  SORENESS THAT HAS LASTED OVER 1 MONTH.
Had dose #2 of SHINGRIX vaccine 9pm Thursday, 1/3/19. Having nausea (no vomiting yet) from 2:30am Friday, 1/4/19 up until & including now (Noon 1/4/19). Also, pain in muscle upon injection, and still having pain in muscle 15 hours later.
Tested  COVID positive; This spontaneous case was reported by an other health care professional (subsequently medically confirmed) and describes the occurrence of COVID-19 (Tested  COVID positive) in a 39-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011J20A) for COVID-19 vaccination.     No Medical History information was reported.   On 22-Dec-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form.   On 28-Dec-2020, the patient experienced COVID-19 (Tested  COVID positive). At the time of the report, COVID-19 (Tested  COVID positive) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 28-Dec-2020, SARS-CoV-2 test positive: positive (Positive) Positive.   The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter. No treatment information was provided.; Sender's Comments: Very limited information regarding these events has been provided at this time. The patient probably experienced asymptomatic COVID-19 infection before being administered with the mRNA-1273 vaccine.
Systemic: Seizure-Medium, Additional Details: Patient had a seizure, 24 hours post vaccine. Patient went to ER where they found a subdural hematoma
I received my 1st dose in my left arm around 11:30AM and about 9:00PM, I started noticing muscle and joint pain in my right arm. That persisted for ten days. It was difficult to perform daily activities. After ten days, my right arm felt better, but the joint and muscle pain moved to my left arm. This still hindered me from performing daily activities. About 5-6 days later, I started to experience this pain in both arms at the same time. This continued after receiving my second dose also. The total amount of time I was in pain was about seven months.
Fever, chills, body shakes, nausea, weakness for 2 and a half days. Tylenol and Motrin taken, along with Vitamin C chewable.
I had typical side effects and none requiring medical attention.  I am breastfeeding my 9 month old daughter and she is hot, irritable as well.  It?s mild and not requiring medical attention but should be noted.
Tinnitus developed within 1 -2 hours after receipt of vaccine and persists.  It was most intense the first couple of weeks.  It is less bothersome now but there are daily waves of it being quite loud.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 59 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 05Mar2021 13:30 (Lot number: EN6199) at the age of 59 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. The patient took concomitant medications. Past drug history included: Novocaine, reaction(s): "Known allergies: novacaine". The following information was reported: TINNITUS (non-serious) with onset 05Mar2021 14:30, outcome "not recovered", described as "Tinnitus developed within 1 -2 hours after receipt of vaccine and persists.  It was most intense the first couple of weeks.  It is less bothersome now but there are daily waves of it being quite loud.". The event "tinnitus developed within 1 -2 hours after receipt of vaccine and persists.  it was most intense the first couple of weeks.  it is less bothersome now but there are daily waves of it being quite loud." was evaluated at the physician office visit. Therapeutic measures were not taken as a result of tinnitus.  No follow-up attempts are possible. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021438317 similar report from same reporter
beginning 2wk p/vax severe h/a, migraines, anorexia, short term nausea, fatigue, memory problems, stiff, sore neck & shoulders, low back pain, sever pain in all the joints in hands;
The patient got the injection around 11 AM and experience swelling of the lip and cheek at 6pm.  Patient thought it was onset of a cold sore and followed up later after she was experiencing pain trying to chew.  The doctors told her there was nothing they could give her and to monitor for severe anaphylaxis per patient mother.
Influenza vaccine injected intradermally to patient. Patient developed swelling, erythema, warmth with tenderness. Treated with antibiotic with improvement.
Pt presented with afebrile new onset seizure disorders - generalized tonic/clonic. Transferred to medical center. Nl EEG & MRI. Continued to have brief seizures despite being started on KEPPRA.
Myalgia, Diarrhea, NauseaVomiting, SORE ARM, LISTLESSNESS Narrative:
Client received vaccines, stood up and was waiting for mother. C/O being thirsty, then of dizziness and then fainted. Was unconscious for about 20-30 seconds. Regained consciousness when feet were elevated. Vital signs were WNL. Client was pale and diaphoretic. Given fluids and crackers, observed for about 30 minutes and left with mother in stable condition. Call given to mother on 10-18-10 and child has some weakness for about 24 hours. Doing well on 10-18-10.
Severe stomach cramps; Diarrhea; This spontaneous case was reported by a patient and describes the occurrence of ABDOMINAL PAIN UPPER (Severe stomach cramps) and DIARRHOEA (Diarrhea) in a 53-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.    Co-suspect products included non-company products COVID-19 VACCINE NRVV AD26 (JANSSEN COVID-19 VACCINE) for COVID-19 prophylaxis and ADALIMUMAB (HUMIRA) for Panuveitis.    The patient had no known allergies and no reported medical history.  Concurrent medical conditions included Panuveitis (Non-infectious intermediate, posterior and Panuveitis).   On 23-Jun-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Jun-2022, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 40 milligram. On an unknown date, the patient received first dose of COVID-19 VACCINE NRVV AD26 (JANSSEN COVID-19 VACCINE) (Intramuscular) 1 dosage form. On an unknown date, received second dose of COVID-19 VACCINE NRVV AD26 (JANSSEN COVID-19 VACCINE) (Intramuscular) dosage was changed to 1 dosage form. On 25-Jun-2022, the patient experienced ABDOMINAL PAIN UPPER (Severe stomach cramps) and DIARRHOEA (Diarrhea). At the time of the report, ABDOMINAL PAIN UPPER (Severe stomach cramps) and DIARRHOEA (Diarrhea) outcome was unknown.            Concomitant medications were not reported.   Treatment medications were not reported.
Information has been received from a healthcare worker (medical assistant) referring to a patient of unknown gender and age. The information of concurrent conditions, medical history and concomitant medications was not provided. On 15-OCT-2015 (reported as "today"), the patient was administered an expired dose of the Pediatric/Adolescent Formulation of VAQTA 25/0.5 (unit not provided) vial (lot # J012768, expired date 25-SEP-2015, dose and frequency were not provided) intramuscularly. This was the first dose of VAQTA this patient had been administered. No adverse effect was reported. Additional information has been requested.
Injection site pain, Body aches, Fever, Rash, Swollen Lymph nodes
pt recv vax; mom rpt walnut size lump in leg where DTP/HIB was adm;
Missed last dose of Vivotif; A spontaneous report was received from a patient on 19AUG2022. It described a female patient (unknown age) who "missed last dose of Vivotif (PT: Product dose omission issue). The patient was taking Vivotif (typhoid vaccine live oral Ty21A) for immunization. The patient reported that her fourth dose of Vivotif was due to be taken last night (at the time of reporting) around 9:30 PM, however, she missed the dose because she lost the last dose of Vivotif. The outcome of the reported event was not applicable.  Action taken with Vivotif with respect to the reported event was not applicable.  No additional information was reported.  Company comment: It was reported that a consumer missed last dose of Vivotif (product dose omission issue). Vivotif dose should be taken every other day, and the causality of product dose omission issue is not applicable to Vivotif considering the nature of the event. The case is considered non-serious as per medical assessment.; Sender's Comments: It was reported that a consumer missed last dose of Vivotif (product dose omission issue). Vivotif dose should be taken every other day, and the causality of product dose omission issue is not applicable to Vivotif considering the nature of the event. The case is considered non-serious as per medical assessment.
Non stop crying she collapsed when we came home, and slept from 6pm until next morning 9am without waking she never slept a night before or since that day. The next 17 days she had a fever she was hot and cold flashes she was crying crying so sad, she is healthy a non cry baby-happy-not these 17 days and her nose was running 17 days. She had very difficult to breath, the injection site were red and hard for several days following. So far she seem to have grown less before she was growing so much the first 3m. then she seemed to have slowed down her growth rate. She seems fine now.
1 Week after my 2nd dose I developed a rash on my lower right leg. It became very itchy and red. I was prescribed a topical cream to use. Over the course of the next 4 weeks the rash got bigger and spread to the left lower leg.  I was prescribed different topical creams, had a Kenalog injection but nothing was working. The itch was temporarily relived by the Kenalog injection.  I ended up getting a punch biopsy and it was determined that I had eczema in parts of my leg. I was referred to a dermatologist and was also told I had hives as well and was put on a 2 week antihistamine regimen.   Also, 1 week after my 2nd dose my mentral cycle lasted 36 days and my period was about 7 days long. This continued for 2 months. My cycles usually are 24-27 days and my period is only usually 4 days, maybe 5 max.
Approximately 53 days later, volume of tinnitus increased dramatically, Led to 3 nights of sleeplessness . Led to migraines and vertigo. My internist Dr referred me to the Clinic who said the increased volume in tinnitus was not related to my ears. Dr prescribed a contrast MRI. THere was an inconclusive finding on the first MRI, so I had a second MRI. The second MRI showed there was no pathology in the brain. I then went to a neurologist. He diagnosed my headaches and vertigo as being Migraines and said the increased loudness of my tinnitus was due to the migraines. Ive been on headache migrain pain medication for weeks including Emgality, excedrin for migraines,zofran for vertigo and nothing has lowered the volume of the tinnitus.l
Information has been received from a registered nurse at a dermatology office, concerning a 17 year old female patient who on 20-SEP-2006 was vaccinated with the first dose of Gardasil (Lot #653736/0868F), and on 05-JAN-2007, with the second dose of Gardasil (Lot #655165/1425F) at an OB-GYN office. The nurse reported that on 05-JAN-2007, following the second vaccination, the patient, immediately got at bump on the right arm," by approximately 19-JAN-2007 ("within 2 weeks of the vaccination"), the patient's "arm was cabby, scaly and bigger, than spread to whole body and face;" the patient developed a severe rash with itching. Prior to the first visit at the dermatology office, the nurse confirmed that the patient reported she had received treatment (date not specified) from a clinic, involving 2 courses of methylprednisone and cephalexin. On 27-JAN-2007, when the patient initially visited the dermatology office, the nurse indicated that the rash "looked like a sunburn that had peeled, was swollen, flaked and scabbed." Treatment on 27-JAN-2007 included an injection of DEPO-MEDROL), MOISTEREL cream (OTC). At the time of this report, it was unknown if the patient had recovered; the patient had a follow up visit scheduled at the dermatology office for 17-APR-2007. The reporter considered the severe rash with itching, peeling, swelling, flaking and scabbing to be disabling as the patient had missed school, and also an other medical event. Additional information has been requested.
The day after the Pfizer booster vaccine, pt started developing myalgias, arthralgias, fever. Now she is having shortness of breath, fever, left arm swelling and tenderness, left axilla lymphadenopathy, dark colored urine.
This spontaneous report as received from a healthcare worker refers to a 59 year old female patient. The patient has morphine allergy, penicillin allergy, iodine allergy, latex - unspecified allergies and sulfa allergy. On 29-OCT-2013, the patient was vaccinated with a 0.5 ml of PNEUMOVAX23 (lot # J004196, expiry date 06-DEC-2014, route was subcutaneous). Concomitant medications were none. On 29-OCT-2013, the patient experienced burning pain of her left arm and chills two hours after receiving PNEUMOVAX23. The patient sought medical attention. On 31-OCT-2013, the patient saw the physician in the office and was treated with KEFLEX. Patient received treatment with antibiotics and KEFLEX (500 mg/three times a day/for 10 days). Later the patient was admitted to the hospital for pain and cellulitis. The outcome of the events were unknown. Additional information has been requested.
pt recvd vax; was sleeping a great deal but was aroused & nl when awake;advised to call MD;sxs cont w/ apnea;adm to hosp w/ shock collapse;
Miscarriage Got my first Moderna shot on 04/03/2021, second Moderna shot on 05/05/2021. Cramping on April 26, 2021 as I was 5 weeks pregnant, bleeding on 05/06/2021 confirming miscarriage.  Last period was 03/25/2021, due date was planned 12/30/2021.
3 days after receiving the Covid vaccination, the patient tested positive for Covid. THe pt began to deteriorate and was admitted 10 days post vaccination and required oxygen support. Pt continued to experiences Covid pneumonia.
Onset occurred approx 4 hours after administration. Erythema, edema, warmth, severe pain all localized at injection site. Size of erythema/edema-circular 3' in diameter.
Lethargy after receiving Moderna vaccine; This spontaneous case was reported by a consumer and describes the occurrence of LETHARGY (Lethargy after receiving Moderna vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced LETHARGY (Lethargy after receiving Moderna vaccine). At the time of the report, LETHARGY (Lethargy after receiving Moderna vaccine) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information was not provided.   Most recent FOLLOW-UP information incorporated above includes: On 01-Sep-2021: Follow-up received contains no new information.
I63.9 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 2/26/2022 DYSARTHRIA, LATE EFFECT OF ISCHEMIC STROKE I63.9 ACUTE STROKE DUE TO ISCHEMIA, UNSPECIFIED TYPE AND ARTERY 2/26/2022 HYPONATREMIA
Patient initially reported symptoms of body aches to jail officer at 10:00 and requested ice pack.  Jail nurse provided details of symptoms at 12:15 am 5/20/21 as the following report from officer  "He (jail officer) said he had the following symptoms: severe body pain, muscles felt like they were burning, confusion, severe headache. Officers noted lip swelling, weakness, and confusion. They had to help him walk. According to ED notes he was given Benadryl, Ibuprofen and a bag of fluids. They (ED) did a CBD and Metabolic/Electrolyte Panel."
Pt reports that an inch or so below injection site down to her elbow is bright pink and warm to the touch. Started the day after vaccination. Has been getting better per the patient report.
Became ill with Covid a month after receiving the second dose. Had many symptoms including: fever, chills, stuffy nose, body aches, nausea, diarrhea, sore throat, fatigue, loss of taste and smell.
Pt called approximately 4-5 hours after receiving vaccine with difficulty swallowing. No shortness of breath. Sent to ER
This spontaneous report as received from a pharmacist refers to a newborn female patient of unknown age. On 31-OCT-2012 08:00, the patient was vaccinated with RECOMBIVAX HB that had been exposed to temperatures below 32F for 6 hours. During that 6 hour time period, the vaccine was exposed to 28.8F for 1.5 hours. Administration route was not reported. Two lot# were involved and the lot# were reported as: 0294AE, expiry date on 06-SEP-2014; and 0385AE, expiry date on 08-NOV-2014. It was unspecified which lot# the patient was administered. The outcome of event was unknown. It was unspecified if the patient sought medical attention. This is one of several reports received from the same source. Additional information has been requested.
15 minutes after vaccination patient reported she felt like she would pass out. Patient pale, sweaty. Patient pulse dropped from 79 to 52. BP unable to be obtained. Patient pupils dilated. Patient did lose consciousness briefly. Kept for 30 extra min observation (45 min total). Patient discharged in stable condition.
Severe tinnitus.  High pitching constant ringing.  Have seen GP and ENT doctors and there is no treatment.